Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-123.

Mancuso CJ, Magro CM, Lipner SR. Acquired digital fibrokeratoma presenting as a painless nodule on the right fifth fingernail. Cutis. 2019;103(6):340-342.

Starza ID, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, et al. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2838-2840.

Zhong E, Scognamiglio T, D'Alfonso T, Song W, Tran H, Baek I, et al. Breast Tumor Resembling the Tall Cell Variant of Papillary Thyroid Carcinoma: Molecular Characterization by Next-Generation Sequencing and Histopathological Comparison With Tall Cell Papillary Carcinoma of Thyroid. Int J Surg Pathol. 2019;27(2):134-141.

Gaudino MF, Lorusso R, Ohmes LB, Narula N, McIntire P, Gargiulo A, et al. Open radial artery harvesting better preserves endothelial function compared to the endoscopic approach. Interact Cardiovasc Thorac Surg. 2019;29(4):561-567.

Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation. Diagn Cytopathol. 2019;47(10):977-985.

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol. 2019;249(1):79-89.

Penney KL, Loda M, Stampfer MJ. Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eu. Eur Urol. 2019;75(3):e54-e55.

Cushing MM, DeSimone RA, Goel R, Hsu Y-, Parra P, Racine-Brzostek SE, et al. The impact of Daratumumab on transfusion service costs. Transfusion. 2019;59(4):1252-1258.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019;10(1):4358.